September 28, 2016—The New York Times published a shocking article this morning about how drug companies tried to strong-arm a patient-advocacy group to keep quiet about obscenely high drug prices. As we’ve noted before, stories like these raise questions about what’s motivating some disease-awareness groups to bad-mouth the 340B drug discount program.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)